Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal
Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal
Crown Laboratories, Inc., a privately held player in the skincare industry, agreed on Monday to acquire Revance Therapeutics, Inc. (NASDAQ:RVNC).
皇冠實驗室是護膚品行業的一傢俬營企業，已於週一同意收購Revance Therapeutics, Inc.（納斯達克：RVNC）。
Under the terms of the agreement, Crown will commence a tender offer to acquire all outstanding shares of Revance's common stock for $6.66 per share in cash, representing a total enterprise value of $924 million.
根據協議條款，皇冠將以6.66美元的現金方式發起要約收購Revance普通股的所有未流通股份，代表總企業價值爲9,2400萬美元。
The purchase price represents a premium of 89% over Revance's closing market price on Aug. 9, 2024, and a 111% premium to Revance's 60-day volume-weighted average price.
收購價代表89%溢價，高於2024年8月9日的Revance收盤市場價以及Revance 60天加權平均價的111%。
Also Read: Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings.
同樣閱讀：肉毒桿菌和類似注射劑有相關風險：消費者組織推動加強警告。
Revance Therapeutics' lead product, Daxxify (daxibotulinumtoxinA-Ianm) injection, is indicated to treat frown lines. It competes with AbbVie Inc's (NYSE:ABBV) Botox.
Revance Therapeutics的主打產品Daxxify（daxibotulinumtoxinA-Ianm）注射劑，用於治療皺紋。與AbbVie Inc.（紐交所：ABBV）的Botox競爭。
The FDA approved Revance's Daxxify in September 2022.
FDA於2022年9月批准了Revance的Daxxify。
Revance's Daxxify is known for its longer-lasting effects, lasting approximately six months, almost double the duration of Botox.
Revance的Daxxify以其持久的效果而聞名，在持續約六個月的時間內，幾乎是Botox持續時間的兩倍。
In the second quarter of 2024, Daxxify generated sales of $28.69 million, up from $22.63 million a year ago. Daxxify aesthetic units sold increased 65% year-over-year and 15% sequentially; over 3,700 ordering accounts were reached.
2024年第二季度，Daxxify的銷售額爲2869萬美元，比去年同期的2263萬美元增長27%。Daxxify的銷售量同比增長65%，環比增長15%；達到超過3,700個訂購帳戶。
Jeff Bedard, founder and Chief Executive Officer of Crown, praised Revance for its "impressive track record in developing innovative aesthetics offerings that will complement Crown's innovative line of skincare products."
皇冠公司的創始人兼首席執行官Jeff Bedard，讚揚Revance在開發創新美容產品方面具有「令人印象深刻的成績單，將補充皇冠創新的護膚產品線」。
The transaction is expected to close by year-end. Following the merger, Revance will be wholly owned by Crown, and its stock will no longer be publicly traded on Nasdaq.
預計交易將於年底完成。合併後，Revance將完全歸皇冠所有，其股票不再公開交易於Nasdaq。
Price Action: RVNC stock is up 86.3% at $6.57 at last check Monday.
股價走勢：截至週一最後檢查，RVNC股票上漲86.3%，爲6.57美元。
- Delay Hits Humacyte's Bioengineered Human Tissue Implant For Vascular Trauma Injuries, FDA Extends Time To Review.
- Humacyte的生物工程人體組織移植物用於血管創傷性損傷的延遲，FDA延長了審查時間。